Avalon Pharmaceuticals to Present at 20th Annual Roth Capital Partners Growth Stock Conference

  
    
  
  
    
      Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced that C. Eric 
      Winzer, Executive Vice President and CFO, will provide an update on the 
      Company at the 20th Annual Roth Capital Partners 
      Growth Stock Conference.
    
    
      The conference will be held at The Ritz Carlton in Laguna Niguel, CA, 
      February 18-21. Mr. Winzer is scheduled to present on Tuesday, February 
      19, at 11:00am.
    
    
      About Avalon Pharmaceuticals
    
    
      Avalon is a biopharmaceutical company focused on the discovery, 
      development and commercialization of first-in-class cancer therapeutics. 
      Avalon’s lead product candidate, AVN944, an 
      IMPDH inhibitor, is in Phase II clinical development. Avalon also has 
      preclinical programs to develop inhibitors of the Beta-catenin and 
      Aurora/Centrosome pathways, discovery programs for inhibitors of the 
      Survivin and Myc pathways and partnerships with Merck, MedImmune, 
      ChemDiv, Medarex, and Novartis. AvalonRx® 
      is the company’s proprietary platform which is 
      based on large-scale biomarker identification and monitoring, used to 
      discover and develop therapeutics for pathways that have historically 
      been characterized as "undruggable." Avalon is headquartered in 
      Germantown, MD.
    
    
      Safe Harbor Statement
    
    
      This announcement contains, in addition to historical information, 
      certain forward-looking statements that involve risks and uncertainties. 
      Such statements reflect the current views of Avalon management and are 
      based on certain assumptions. Actual results could differ materially 
      from those currently anticipated as a result of a number of factors, 
      risks and uncertainties, including those specified under the “Risk 
      Factors” section of our 2006 Annual Report on 
      Form 10-K and updates contained in subsequent filings we make with the 
      Securities and Exchange Commission.